JP2011519873A - 認知欠損を治療する方法 - Google Patents

認知欠損を治療する方法 Download PDF

Info

Publication number
JP2011519873A
JP2011519873A JP2011507792A JP2011507792A JP2011519873A JP 2011519873 A JP2011519873 A JP 2011519873A JP 2011507792 A JP2011507792 A JP 2011507792A JP 2011507792 A JP2011507792 A JP 2011507792A JP 2011519873 A JP2011519873 A JP 2011519873A
Authority
JP
Japan
Prior art keywords
disorder
trimethylpiperazine
chloro
trans
phenylindan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519873A5 (https=
Inventor
ホルム・レネー
カウ・クリスティネ
ヴィルムセン・ビルギッテ
ヘルテル・クラウス・ペーター
オルセン・クリスティナ・クッレ
ブルーン・ロネ
セビュ・カリナ・クレヤー
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2011519873A publication Critical patent/JP2011519873A/ja
Publication of JP2011519873A5 publication Critical patent/JP2011519873A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011507792A 2008-05-07 2009-05-07 認知欠損を治療する方法 Pending JP2011519873A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200800647 2008-05-07
DKPA200800647 2008-05-07
DKPA200801392 2008-10-03
DKPA200801392 2008-10-03
DKPA200801519 2008-11-04
DKPA200801519 2008-11-04
PCT/DK2009/050107 WO2009135495A1 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Publications (2)

Publication Number Publication Date
JP2011519873A true JP2011519873A (ja) 2011-07-14
JP2011519873A5 JP2011519873A5 (https=) 2012-06-21

Family

ID=40870955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507792A Pending JP2011519873A (ja) 2008-05-07 2009-05-07 認知欠損を治療する方法

Country Status (15)

Country Link
US (2) US20090306092A1 (https=)
EP (1) EP2285377A1 (https=)
JP (1) JP2011519873A (https=)
KR (1) KR20110021754A (https=)
CN (1) CN102065861B (https=)
AU (1) AU2009243813B2 (https=)
BR (1) BRPI0912223A2 (https=)
CA (1) CA2722374A1 (https=)
CO (1) CO6311083A2 (https=)
EA (1) EA018927B1 (https=)
IL (1) IL209084A0 (https=)
MX (1) MX2010012037A (https=)
NZ (1) NZ589571A (https=)
WO (1) WO2009135495A1 (https=)
ZA (1) ZA201007912B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022509408A (ja) * 2018-10-29 2022-01-20 ハー・ルンドベック・アクチエゼルスカベット 非晶性の式（ｉ）の化合物及び非晶性の式（ｉ）の化合物塩

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
JO3421B1 (ar) * 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502783A (ja) * 2003-08-18 2007-02-15 ハー・ルンドベック・アクチエゼルスカベット トランス−４−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−１，２，２−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法
WO2007137820A1 (en) * 2006-05-30 2007-12-06 Elbion Gmbh PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
DE69913332T2 (de) * 1998-05-01 2004-05-27 Pfizer Products Inc., Groton Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
IN187170B (https=) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
IL162666A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2004039322A2 (en) * 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
TW200640891A (en) * 2005-02-16 2006-12-01 Lundbeck & Co As H Tartrate and malate salts of a pharmarceutical compound
US20080269248A1 (en) * 2005-02-16 2008-10-30 H. Lundbeck A/S Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502783A (ja) * 2003-08-18 2007-02-15 ハー・ルンドベック・アクチエゼルスカベット トランス−４−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−１，２，２−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法
WO2007137820A1 (en) * 2006-05-30 2007-12-06 Elbion Gmbh PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013040338; Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏ．３８, 1995, ｐ．４３８０-４３９２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022509408A (ja) * 2018-10-29 2022-01-20 ハー・ルンドベック・アクチエゼルスカベット 非晶性の式（ｉ）の化合物及び非晶性の式（ｉ）の化合物塩
JP7442538B2 (ja) 2018-10-29 2024-03-04 ハー・ルンドベック・アクチエゼルスカベット 非晶性の式（ｉ）の化合物及び非晶性の式（ｉ）の化合物塩

Also Published As

Publication number Publication date
IL209084A0 (en) 2011-01-31
WO2009135495A1 (en) 2009-11-12
CO6311083A2 (es) 2011-08-22
ZA201007912B (en) 2012-02-29
HK1157674A1 (en) 2012-07-06
AU2009243813B2 (en) 2014-05-29
KR20110021754A (ko) 2011-03-04
EP2285377A1 (en) 2011-02-23
NZ589571A (en) 2012-07-27
CN102065861A (zh) 2011-05-18
MX2010012037A (es) 2010-11-30
CN102065861B (zh) 2013-10-16
AU2009243813A1 (en) 2009-11-12
CA2722374A1 (en) 2009-11-12
BRPI0912223A2 (pt) 2015-10-06
US20090306092A1 (en) 2009-12-10
EA201071273A1 (ru) 2011-06-30
US20110207744A1 (en) 2011-08-25
EA018927B1 (ru) 2013-11-29

Similar Documents

Publication Publication Date Title
Davies et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology
Bhana et al. Olanzapine: an updated review of its use in the management of schizophrenia
Keck et al. Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis
Byerly et al. Antipsychotic medications and the elderly: effects on cognition and implications for use
Miyamoto et al. Antipsychotic drugs
Costall et al. Anxiolytic potential of 5‐HT3 receptor antagonists
CN102065861B (zh) 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
JP2012504560A (ja) 経口製剤
Meneses et al. 5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
Grossman A review of anticonvulsants in treating agitated demented elderly patients
Wolff et al. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat
CN103108548A (zh) 使用环酰胺衍生物治疗σ受体介导的病症的方法
Higgins et al. Studies to examine potential tolerability differences between the 5-HT2C receptor selective agonists lorcaserin and CP-809101
Marona-Lewicka et al. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats
Ballard et al. The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
HK1157674B (en) Use of trans-4((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for improving cognition
Nordquist et al. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils
Rashid et al. Phenothiazines and related antipsychotic drugs
Cada et al. Aripiprazole
Marek Developing serotonergic antidepressants acting on more than the serotonin transporter
TW200946120A (en) Method for treating cognitive deficits
Ayd Jr Tardive dyskinesia: Recent developments
Norman Multi-modal Pharmacological Treatments for Maj-or Depressive Disorder: Testing the Hypothesis
Gommans et al. Two-lever drug–drug discrimination with the 5-HT1 receptor agonists flesinoxan and eltoprazine
Galasko Pharmacological approaches to behavioral symptoms in Alzheimer's disease

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120214

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304